Engaging and Empowering Stakeholders to Advance Pharmacogenomics

Crisamore, Karryn; Nolin, Thomas D.; Coons, James C.; Empey, Philip E.

doi:10.1002/cpt.1470

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clopidogrel– CYP2C19 implementation successes need to be contrasted with the difficulties faced in the implementation of warfarin– CYP2C9/CYP4F2/VKORC1 PGx. The key enablers for clopidogrel– CYP2C19 implementation include a discrete patient population (post-PCI), single-gene testing, a high frequency of actionable results, clinically well-established alternative therapies, and a focused group of providers (interventional cardiologists) (Crisamore et al, 2019 ).…”

Section: Pgx Implementationmentioning

confidence: 99%

Cardiovascular precision medicine – A pharmacogenomic perspective

Padmanabhan¹,

Toit²,

Dominiczak³

2023

Camb. prisms Precis. med.

View full text Add to dashboard Cite

Precision medicine envisages the integration of an individual’s clinical and biological features obtained from laboratory tests, imaging, high-throughput omics and health records, to drive a personalised approach to diagnosis and treatment with a higher chance of success. As only up to half of patients respond to medication prescribed following the current one-size-fits-all treatment strategy, the need for a more personalised approach is evident. One of the routes to transforming healthcare through precision medicine is pharmacogenomics (PGx). Around 95% of the population is estimated to carry one or more actionable pharmacogenetic variants and over 75% of adults over 50 years old are on a prescription with a known PGx association. Whilst there are compelling examples of pharmacogenomic implementation in clinical practice, the case for cardiovascular PGx is still evolving. In this review, we shall summarise the current status of PGx in cardiovascular diseases and look at the key enablers and barriers to PGx implementation in clinical practice.

show abstract

Section: Pgx Implementationmentioning

confidence: 99%

Cardiovascular precision medicine – A pharmacogenomic perspective

Padmanabhan¹,

Toit²,

Dominiczak³

2023

Camb. prisms Precis. med.

View full text Add to dashboard Cite

show abstract

“…Even if an institution is supportive of PGx, successful implementation depends on enthusiastic individuals willing to take on lead roles. Crissamore et al 33 point out that engaging and empowering stakeholders and a broad range of disciplines and specialties through clinician champions are crucial to promote the uptake of evidence-based interventions, including PGx. The authors provide examples of their own experiences, offer frameworks of expanding implementation, and thoughts on paths forward.…”

Section: Strive For Progress Not Perfection (Unknown)mentioning

confidence: 99%